abstract |
The present invention generally relates to the field of immunomodulation. Agents for inhibiting immune stimulation mediated by Toll-like receptors are taught herein, which are useful in the treatment of viral and microbial diseases, diseases involving autoimmune and inflammatory elements, and cancer. This agent antagonizes the formation of a disulfide bond between C98 and C475 of Toll-like receptor 7 (TLR7), thereby preventing TLR7 activation. Also implemented herein are pharmaceutical compositions. |